Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841854 | 1.00 | POLB (0.41) | POLBMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL15075199 | 1.00 | POLB (0.41) | POLBMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL365556 | 0.88 | MAPT (0.40) | POLBMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL28965750 | 0.82 | MAPT (0.38) | POLBMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL28965747 | 0.82 | MAPT (0.38) | POLBMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL3456621 | 0.80 | TSHR (0.35) | L3MBTL1MAPTKDM4ECYP2C9ALDH1A1 | |
| SCHEMBL14279177 | 0.78 | MAPT (0.42) | POLBMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL15790744 | 0.77 | MAPT (0.35) | POLBMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL120745 | 0.77 | GLO1 (0.64) | POLBMEN1KMT2ATDP1GAA | |
| SCHEMBL5902452 | 0.77 | GLO1 (0.31) | CYP2C9GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262192-A1 | QUINAZOLINE DERIVATIVES SUITABLE FOR USE AS WERNER SYNDROME HELICASE PROTEIN INHIBITORS | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| CN-110520413-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-4074708-A1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | Immunic AG (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3679034-B1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | IMMUNIC AG (DE) | 2022-06-01 | — | — | EP | disclosed |
| US-11292788-B2 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IMMUNIC AG (DE) | 2022-04-05 | — | — | US | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| WO-2009029384-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-1999114-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. Hoffmann-la Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107470-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
| EP-1119529-B1 | CHEMICAL CONSTRUCTS | GLAXO GROUP LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| EP-1119528-B1 | CHEMICAL CONSTRUCTS AND THEIR USES | GLAXO GROUP LTD (GB) | 2002-08-28 | — | — | EP | disclosed |
| EP-1119529-A2 | CHEMICAL CONSTRUCTS | GLAXO GROUP LIMITED (GB) | 2001-08-01 | — | — | EP | disclosed |
| EP-1119528-A2 | CHEMICAL CONSTRUCTS AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020357-A2 | CHEMICAL CONSTRUCTS | GLAXO GROUP LIMITED (GB) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020112-A2 | CHEMICAL CONSTRUCTS AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD3B2, HSD3B1, HSD17B2 | POLB 1549/4885MEN1 1594/4885KMT2A 3407/4885 |
| US-11292788-B2 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IFNG, IL17A, IFNAR1 | POLB 728/4885MEN1 2528/4885KMT2A 1459/4885 |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | POLB 2336/4885MEN1 2531/4885KMT2A 3283/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | POLB 2336/4885MEN1 2531/4885KMT2A 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.